Streetbeat News

Stock Prices

CYD

The first batch of green energy buses equipped with Yuchai Xingshunda hydrogen fuel cells has been launched. This development is significant for the green energy sector and highlights the advancements in hydrogen fuel cell technology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:17 am

CTXR

Citius Pharmaceuticals announced that its Phase 3 trial of Mino-Lok met its primary endpoint, showing a statistically significant improvement in the time to failure event compared to the control arm patients receiving clinician-directed anti-infective lock solution.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:16 am

AZN

AstraZeneca (NASDAQ: AZN) has announced an ambitious plan to increase its total revenue to $80 billion by 2030, up from $45.8 billion in 2023. The growth will be driven by expanding its oncology, biopharmaceuticals, and rare disease portfolios, and introducing 20 new medicines by the end of the decade. The company will also invest in transformative technologies and platforms to sustain growth beyond 2030. AstraZeneca aims to achieve a mid-30s percentage core operating margin by 2026 and maintain it post-2026. Analysts have mixed views on the revenue target, with some seeing a 20% upside to the 2030 consensus.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 11:16 am

AZO

IWM

LOW

M

NVDA

PANW

QQQ

SPY

TOL

URBN

VSAT

ZM

Wall Street is expected to open mostly flat as traders await Nvidia's earnings and several Fed speeches. Bitcoin surged above $71K on Ethereum ETF approval speculation. Key stocks in focus include Nvidia, Palo Alto Networks, Zoom Video Communications, Lowe's, AutoZone, Macy's, Toll Brothers, Viasat, and Urban Outfitters.

Portfolio Pulse from Shanthi Rexaline

May 21, 2024 | 11:14 am

YMM

Full Truck Alliance shares are trading higher following a Q1 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:11 am

GLUE

Monte Rosa Therapeutics will present preclinical data at Digestive Disease Week 2024, showing that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein with potential to treat multiple autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:09 am

LRCX

Lam Research shares are trading higher after the company announced a $10 billion buyback authorization and a stock split.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:08 am

LRCX

Lam Research has announced a $10 billion stock buyback authorization and a 10-for-1 stock split, effective after the close on October 2.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:08 am

YMM

Full Truck Alliance Co (NYSE:YMM) reported Q1 2024 earnings of $0.10 per share, beating the analyst estimate of $0.07 by 42.86%. The company also reported sales of $314.212 million, surpassing the estimate of $313.193 million. Both earnings and sales showed significant year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:07 am

ASLN

ASLAN Pharmaceuticals announced a late-breaking poster presentation of translational data on eblasakimab at the American Thoracic Society International Conference.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:07 am